Search research articles
Contact Us
Filters
Showing results (141-150 of 261) with videos related to
Page
of 27
Sort By:
JHEP Reports : Innovation in Hepatology
|
April 18, 2022
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease
Aidan J McGlinchey, Olivier Govaere, Dawei Geng, et al.
Cell Reports. Medicine
|
November 20, 2024
Hepatic glucose production rises with the histological severity of metabolic dysfunction-associated steatohepatitis
Silvia Sabatini, Partho Sen, Fabrizia Carli, et al.
Molecular Metabolism
|
April 9, 2023
The GCKR-P446L gene variant predisposes to raised blood cholesterol and lower blood glucose in the P446L mouse-a model for GCKR rs1260326
Brian E Ford, Shruti S Chachra, Katrina Rodgers, et al.
Hepatology (Baltimore, Md.)
|
May 28, 2020
Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma
Zoe Hall, Davide Chiarugi, Evelina Charidemou, et al.
Iscience
|
September 6, 2022
Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease
Partho Sen, Olivier Govaere, Tim Sinioja, et al.
Plos One
|
April 19, 2017
A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis
Stuart McPherson, Nina Wilkinson, Dina Tiniakos, et al.
Hepatology Communications
|
November 9, 2020
Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes
Zobair M Younossi, Vincent Wai-Sun Wong, Quentin M Anstee, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 18, 2021
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis
Zobair M Younossi, Maria Stepanova, Fatema Nader, et al.
Journal of Hepatology
|
November 18, 2021
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study
Mary E Rinella, Jean-Francois Dufour, Quentin M Anstee, et al.
Alimentary Pharmacology & Therapeutics
|
October 3, 2023
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis
Stephen A Harrison, Vlad Ratziu, Quentin M Anstee, et al.
Page
of 27
Search research articles
Search
Showing results (141-150 of 261) with videos related to
Sort By:
Page
of 27
JHEP Reports : Innovation in Hepatology
|
April 18, 2022
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease
Aidan J McGlinchey, Olivier Govaere, Dawei Geng, et al.
Cell Reports. Medicine
|
November 20, 2024
Hepatic glucose production rises with the histological severity of metabolic dysfunction-associated steatohepatitis
Silvia Sabatini, Partho Sen, Fabrizia Carli, et al.
Molecular Metabolism
|
April 9, 2023
The GCKR-P446L gene variant predisposes to raised blood cholesterol and lower blood glucose in the P446L mouse-a model for GCKR rs1260326
Brian E Ford, Shruti S Chachra, Katrina Rodgers, et al.
Hepatology (Baltimore, Md.)
|
May 28, 2020
Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma
Zoe Hall, Davide Chiarugi, Evelina Charidemou, et al.
Iscience
|
September 6, 2022
Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease
Partho Sen, Olivier Govaere, Tim Sinioja, et al.
Plos One
|
April 19, 2017
A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis
Stuart McPherson, Nina Wilkinson, Dina Tiniakos, et al.
Hepatology Communications
|
November 9, 2020
Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes
Zobair M Younossi, Vincent Wai-Sun Wong, Quentin M Anstee, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 18, 2021
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis
Zobair M Younossi, Maria Stepanova, Fatema Nader, et al.
Journal of Hepatology
|
November 18, 2021
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study
Mary E Rinella, Jean-Francois Dufour, Quentin M Anstee, et al.
Alimentary Pharmacology & Therapeutics
|
October 3, 2023
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis
Stephen A Harrison, Vlad Ratziu, Quentin M Anstee, et al.
Page
of 27